Spots Global Cancer Trial Database for prostate specific membrane antigen
Every month we try and update this database with for prostate specific membrane antigen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 | NCT02916537 | Prostate Cancer | CTT1057 Prostatectomy | 18 Years - | Cancer Targeted Technology | |
| PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers | NCT05581979 | Salivary Gland ... Rare Malignant ... | 68-Ga PSMA PET ... | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | NCT04430192 | Prostatic Neopl... | 177Lu-PSMA-617 | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer | NCT05354375 | Immunotherapy | CAR-T cell immu... | 18 Years - 75 Years | The Affiliated Hospital of Xuzhou Medical University | |
| 18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme | NCT04588454 | Glioblastoma Mu... | 18F-PSMA-1007 P... | 18 Years - | Radboud University Medical Center | |
| CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma | NCT03427476 | Renal Cell Carc... | CTT1057 | 18 Years - | Cancer Targeted Technology | |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer | NCT05354375 | Immunotherapy | CAR-T cell immu... | 18 Years - 75 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | NCT04430192 | Prostatic Neopl... | 177Lu-PSMA-617 | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers | NCT05581979 | Salivary Gland ... Rare Malignant ... | 68-Ga PSMA PET ... | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer | NCT03822871 | Prostate Cancer | CTT1403 CTT1057 68Ga-PSMA-11 | 18 Years - | Cancer Targeted Technology | |
| 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy | NCT05155046 | Localized Prost... | 18F-DCFPyL | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
